Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
By W. Kelly, V. Richon, O. O'Connor, T. Curley, Barbara MacGregor-Curtelli, W. Tong, M. Klang, Lawrence H. Schwartz, S. Richardson, E. Rosa and 6 more. Clinical Cancer Research, 2003
659 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/d265b37d49c305587c20865e220b5d3bb411af25
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Peter W. Laird
- Guangdi Wang
- Tien L. Huang
- Madhusoodanan Mottamal
- Shilong Zheng
- Manel Esteller
- Christoph Bock
- Partha M. Das
Citations in the corpus
- Histone Deacetylase Inhibitors: Overview and Perspectives (2007, unknown): “(66) and orally administered drug (67).”
- Cancer epigenetics. (2005, background): “Depudecin Epoxide (214) FK228 Depsipeptide, FR901228 Phase I/II (215) MS-275 Benzamidine Phase I (216) LAQ824 Phase I (217) Oxamflatin (218) MGCD0103 Phase I (219) PXD101 Phase I (220) Pyroxamide Phase I (221) RNAi (222) Suberic Bishydroxamic Acid SBHA (223) Suberoylanilide Hydroxamic Acid SAHA Phas”
- Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents (2015, result): “Similarly deaths were also reported in clinical trials involving vorinostat [66], givinostat [152] and many other HDAC inhibitors.”
- Discovery and development of SAHA as an anticancer agent (2007, background): “Clinical trials with SAHA SAHA administered intravenously to patients with refractory hematologic and solid tumors demonstrated that the drug was well tolerated – with thrombocytopenia and neutropenia being dose limiting in hematologic but not solid tumor patients – and the drug showed significant a”